Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Cancer Medicine Année : 2021

Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.

A. M. Frezza
  • Fonction : Auteur
V. Ravi
  • Fonction : Auteur
S. Lo Vullo
  • Fonction : Auteur
B. Vincenzi
  • Fonction : Auteur
F. Tolomeo
  • Fonction : Auteur
T. W. Chen
  • Fonction : Auteur
P. Teterycz
  • Fonction : Auteur
G. G. Baldi
  • Fonction : Auteur
A. Brunello
  • Fonction : Auteur
N. Hindi
  • Fonction : Auteur
S. Iwata
  • Fonction : Auteur
A. Smrke
  • Fonction : Auteur
A. Fedenko
  • Fonction : Auteur
H. Gelderblom
  • Fonction : Auteur
W. van der Graaf
  • Fonction : Auteur
A. Vozy
  • Fonction : Auteur
E. Connolly
  • Fonction : Auteur
M. Grassi
  • Fonction : Auteur
R. S. Benjamin
  • Fonction : Auteur
J. M. Broto
  • Fonction : Auteur
G. Grignani
  • Fonction : Auteur
R. L. Jones
  • Fonction : Auteur
A. Kawai
  • Fonction : Auteur
A. Tysarowski
  • Fonction : Auteur
L. Mariani
  • Fonction : Auteur
P. G. Casali
  • Fonction : Auteur
S. Stacchiotti
  • Fonction : Auteur

Résumé

Background This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions. Methods Twenty sarcoma reference centres contributed data. Patients with advanced EHE diagnosed from 2000 onwards and treated with systemic therapies, were selected. Local pathologic review and molecular confirmation were required. Radiological response was retrospectively assessed by local investigators according to RECIST. Progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. Results Overall, 73 patients were included; 21 had more than one treatment. Thirty-three patients received anthracyclines regimens, achieving 1 (3%) partial response (PR), 25 (76%) stable disease (SD), 7 (21%) progressive disease (PD). The median (m-) PFS and m-OS were 5.5 and 14.3 months respectively. Eleven patients received paclitaxel, achieving 1 (9%) PR, 6 (55%) SD, 4 (36%) PD. The m-PFS and m-OS were 2.9 and 18.6 months, respectively. Twelve patients received pazopanib, achieving 3 (25%) SD, 9 (75%) PD. The m-PFS and m-OS were.2.9 and 8.5 months, respectively. Fifteen patients received INF-α 2b, achieving 1 (7%) PR, 11 (73%) SD, 3 (20%) PD. The m-PFS and m-OS were 8.9 months and 64.3, respectively. Among 27 patients treated with other regimens, 1 PR (ifosfamide) and 9 SD (5 gemcitabine +docetaxel, 2 oral cyclophosphamide, 2 others) were reported. Conclusion Systemic therapies available for advanced sarcomas have limited activity in EHE. The identification of new active compounds, especially for rapidly progressive cases, is acutely needed.
Fichier principal
Vignette du fichier
Cancer Medicine - 2021 - Frezza - Systemic therapies in advanced epithelioid haemangioendothelioma A retrospective.pdf (551.77 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04305129 , version 1 (24-11-2023)

Licence

Identifiants

Citer

A. M. Frezza, V. Ravi, S. Lo Vullo, B. Vincenzi, F. Tolomeo, et al.. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.. Cancer Medicine, 2021, Cancer Medicine, ⟨10.1002/cam4.3807⟩. ⟨hal-04305129⟩
4 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More